NCT00719888 - Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease | Biotech Hunter

Enrollment

135

Participants

Timeline

Start Date

November 18, 2005

Primary Completion Date

December 22, 2023

Study Completion Date

December 19, 2024

Conditions

Acute Biphenotypic LeukemiaAcute Lymphoblastic LeukemiaAcute Myeloid LeukemiaBurkitt LymphomaChronic Lymphocytic LeukemiaChronic Myelogenous Leukemia, BCR-ABL1 PositiveChronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveFollicular LymphomaLymphoblastic LymphomaLymphoplasmacytic LymphomaMantle Cell LymphomaMarginal Zone LymphomaMyelodysplastic SyndromeMyelofibrosisNon-Hodgkin LymphomaPlasma Cell MyelomaProlymphocytic LeukemiaRefractory AnemiaSmall Lymphocytic Lymphoma

Interventions

DRUG

Cyclophosphamide

Given IV

DRUG

Cyclosporine

Given IV and PO

PROCEDURE

Double-Unit Umbilical Cord Blood Transplantation

Undergo double-unit UCBT

DRUG

Fludarabine

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Mycophenolate Mofetil

Given IV and PO

RADIATION

Total-Body Irradiation

Undergo high-dose or moderate-intensity TBI

PROCEDURE

Umbilical Cord Blood Transplantation

Undergo UCBT

DRUG

Thiotepa

Given IV

Trial Locations (3)

80045

University of Colorado Hospital, Aurora

98101

VA Puget Sound Health Care System, Seattle

98109

Fred Hutch/University of Washington Cancer Consortium, Seattle

All Listed Sponsors

lead

Fred Hutchinson Cancer Center

OTHER